Fourth, the tumor regression triggered by MEK+BCL-XL blockage we reported here using the Alb-R26Met mice is rather impressive, particularly considering the molecular and immune tumor heterogeneity recapitulated by this cancer model and by the drastically remodeling of the immune profile of treated tumors. This evidence concerns the gene MAP2K7 and cancer.